Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8631840 | 0.91 | CA12 (0.50) | LMNACA12CA1CA9ALDH1A1 | |
| SCHEMBL8634539 | 0.91 | CA12 (0.43) | USP2LMNANTRK2CA12CA1 | |
| SCHEMBL8629998 | 0.87 | CA12 (0.43) | USP2LMNANTRK2CA12CA1 | |
| SCHEMBL20261072 | 0.87 | LMNA (0.48) | LMNACA12CA1CA9ALDH1A1 | |
| SCHEMBL25702791 | 0.87 | LMNA (0.48) | LMNACA12CA1CA9ALDH1A1 | |
| SCHEMBL21870585 | 0.85 | NTRK2 (0.33) | USP2LMNANTRK2CA12CA1 | |
| SCHEMBL8633186 | 0.84 | CA12 (0.48) | LMNACA12CA1CA9ALDH1A1 | |
| SCHEMBL8634317 | 0.84 | CA12 (0.41) | USP2LMNACA12CA1CA9 | |
| SCHEMBL26290425 | 0.83 | MGAM (0.46) | USP2LMNANTRK2ALDH1A1KDM4E | |
| SCHEMBL8940796 | 0.82 | MAPT (0.40) | USP2LMNACA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5612382-A | Composition for percutaneous absorption of pharmaceutically active ingredients | Fike, Frances B. (US) | 1997-03-18 | — | — | US | claimed |
| WO-2023250375-A1 | CIRCULAR RNA ENCODING CHIMERIC ANTIGEN RECEPTORS TARGETING BCMA | ORNA THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| EP-4289951-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | Orna Therapeutics, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| WO-2023056033-A1 | LIPID NANOPARTICLE COMPOSITIONS FOR DELIVERING CIRCULAR POLYNUCLEOTIDES | ORNA THERAPEUTICS, INC. (US) | 2023-04-06 | — | — | WO | disclosed |
| WO-2022261490-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2021226597-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| WO-2021189059-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| WO-2021113777-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021030701-A1 | IMPROVED LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS | Acuitas Therapeutics, Inc. (CA) | 2021-02-18 | — | — | WO | disclosed |
| WO-2019036000-A1 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2019-02-21 | — | — | WO | disclosed |
| CN-102428035-B | Halogenated amide biocidal compounds and methods of treating water systems at near neutral to high pH | DOW GLOBAL TECHNOLOGIES LLC | 2014-07-23 | — | — | CN | disclosed |
| CN-102428037-B | Halogenated amide biocidal compounds and methods for treating water systems at near neutral to high PH | DOW GLOBAL TECHNOLOGIES INC | 2014-06-11 | — | — | CN | disclosed |
| WO-2012135669-A1 | NITROGEN RING CONTAINING COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISORDERS | WEINGARTEN M DAVID (US) | 2012-10-04 | — | — | WO | disclosed |
| US-20120238752-A1 | COMPOUND OR ITS TAUTOMER, METAL COMPLEX COMPOUND, COLORED PHOTOSENSITIVE CURING COMPOSITION, COLOR FILTER, AND PRODUCTION | FUJIFILM CORPORATION (JP) | 2012-09-20 | — | — | US | disclosed |
| US-8197994-B2 | Colorant of a dipyrromethene-based metal complex obtained from a metal of iron, zinc, cobalt, copper or vanadium oxide and a dipyrromethene-based compound and a phthalocyanine dye | FUJIFILM CORPORATION (JP) | 2012-06-12 | — | — | US | disclosed |
| US-20120138877-A1 | COMPOUND OR ITS TAUTOMER, METAL COMPLEX COMPOUND, COLORED PHOTOSENSITIVE CURING COMPOSITION, COLOR FILTER, AND PRODUCTION | FUJIFILM CORPORATION (JP) | 2012-06-07 | — | — | US | disclosed |
| EP-0956318-A1 | RADIATION-CURABLE COMPOSITION | DSM N.V. (NL) | 1999-11-17 | — | — | EP | disclosed |
| WO-1998033855-A1 | RADIATION-CURABLE COMPOSITION | DSM N.V. (NL) | 1998-08-06 | — | — | WO | disclosed |
| US-5612382-A | Composition for percutaneous absorption of pharmaceutically active ingredients | Fike, Frances B. (US) | 1997-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238752-A1 | COMPOUND OR ITS TAUTOMER, METAL COMPLEX COMPOUND, COLORED PHOTOSENSITIVE CURING COMPOSITION, COLOR FILTER, AND PRODUCTION | PBRM1, CRY1, MAPT | USP2 1391/4885LMNA 2333/4885NTRK2 4351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.